                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------------- trtn=1 --------------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.TR_TARGET         
                                    Method                               Monotone-data MCMC     
                                    Multiple Imputation Chain            Single Chain           
                                    Initial Estimates for MCMC           EM Posterior Mode      
                                    Start                                Starting Value         
                                    Prior                                Jeffreys               
                                    Number of Imputations                20                     
                                    Number of Burn-in Iterations         200                    
                                    Number of Iterations                 200                    
                                    Seed for random number generator     439384924              


                                                       Missing Data Patterns
 
                                                                     -------------------------Group Means------------------------
  Group    SSNRISN    BASE    WK4    WK12        Freq     Percent         SSNRISN            BASE             WK4            WK12

      1    X          X       X      X              7       77.78        1.857143       34.000000       24.428571       15.142857
      2    X          X       X      O              2       22.22        1.500000       44.500000       10.500000                


 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------------- trtn=1 --------------------------------------------------------------

                                                          The MI Procedure

                                                   EM (Posterior Mode) Estimates
 
                         _TYPE_    _NAME_           SSNRISN            BASE             WK4            WK12

                         MEAN                      1.777778       36.333333       21.333333       17.712466
                         COV       SSNRISN         0.111111       -1.166667       -0.666667       -1.391251
                         COV       BASE           -1.166667       82.714286        7.428571       57.565795
                         COV       WK4            -0.666667        7.428571       68.857143       -3.371313
                         COV       WK12           -1.391251       57.565795       -3.371313       86.476163
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------------- trtn=2 --------------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.TR_TARGET         
                                    Method                               Monotone-data MCMC     
                                    Multiple Imputation Chain            Single Chain           
                                    Initial Estimates for MCMC           EM Posterior Mode      
                                    Start                                Starting Value         
                                    Prior                                Jeffreys               
                                    Number of Imputations                20                     
                                    Number of Burn-in Iterations         200                    
                                    Number of Iterations                 200                    
                                    Seed for random number generator     5725473                


                                                       Missing Data Patterns
 
                                                                     -------------------------Group Means------------------------
  Group    SSNRISN    BASE    WK4    WK12        Freq     Percent         SSNRISN            BASE             WK4            WK12

      1    X          X       X      X              9       56.25        1.777778       35.111111       24.555556       12.444444
      2    X          X       X      O              4       25.00        2.000000       41.500000       21.500000                
      3    X          X       .      X              1        6.25        2.000000       42.000000                       33.000000
      4    X          X       O      O              1        6.25        2.000000       30.000000                                
      5    X          .       .      X              1        6.25        2.000000                                       16.000000
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------------- trtn=2 --------------------------------------------------------------

                                                          The MI Procedure

                                                   EM (Posterior Mode) Estimates
 
                         _TYPE_    _NAME_           SSNRISN            BASE             WK4            WK12

                         MEAN                      1.875000       37.029668       24.659406       14.445187
                         COV       SSNRISN         0.083333        0.479016        0.824705       -0.005220
                         COV       BASE            0.479016       66.704369       -6.289214       30.770182
                         COV       WK4             0.824705       -6.289214       83.471267       21.850775
                         COV       WK12           -0.005220       30.770182       21.850775       66.249026
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------------- trtn=3 --------------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.TR_TARGET         
                                    Method                               Monotone-data MCMC     
                                    Multiple Imputation Chain            Single Chain           
                                    Initial Estimates for MCMC           EM Posterior Mode      
                                    Start                                Starting Value         
                                    Prior                                Jeffreys               
                                    Number of Imputations                20                     
                                    Number of Burn-in Iterations         200                    
                                    Number of Iterations                 200                    
                                    Seed for random number generator     1002394113             


                                                       Missing Data Patterns
 
                                                                     -------------------------Group Means------------------------
  Group    SSNRISN    BASE    WK4    WK12        Freq     Percent         SSNRISN            BASE             WK4            WK12

      1    X          X       X      X              9       64.29        1.888889       39.666667       21.666667       16.555556
      2    X          X       X      O              3       21.43        1.666667       45.000000       27.333333                
      3    X          X       O      O              2       14.29        2.000000       37.500000                                


 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------------- trtn=3 --------------------------------------------------------------

                                                          The MI Procedure

                                                   EM (Posterior Mode) Estimates
 
                         _TYPE_    _NAME_           SSNRISN            BASE             WK4            WK12

                         MEAN                      1.857143       40.500000       22.818214       17.272618
                         COV       SSNRISN         0.090226        0.210526        0.507180        0.299703
                         COV       BASE            0.210526       64.815789       47.376558       17.480979
                         COV       WK4             0.507180       47.376558      124.445653       90.087643
                         COV       WK12            0.299703       17.480979       90.087643       82.803668
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=1 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     439384924              


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      37.063025      23.948830      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=2 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1484397141             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.354354      24.143306      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=3 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     2092774270             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      37.590028      23.481450      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=4 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1477481539             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.644135      24.649090      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=5 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1875900266             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.419042      26.118815      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=6 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     33179711               


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.793575      24.415735      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=7 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1175629672             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.465122      25.636234      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=8 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1498236233             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      37.067187      22.834184      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=9 --------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1742784414             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      37.302870      24.730882      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=10 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     532941029              


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.046223      24.368135      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=11 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     651728871              


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.851315      25.207456      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=12 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     616157876              


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.218184      24.520209      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=13 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     19491595               


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.555429      24.609597      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=14 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     11391642               


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      37.211880      24.240681      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=15 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     2023404355             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.957116      24.319997      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=16 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1178177967             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.406242      22.888898      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=17 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     2081146358             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.475572      24.309782      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=18 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     1320228382             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.718045      24.042608      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=19 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     163093574              


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      37.462043      24.489489      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------------- Imputation Number=20 -------------------------------------------------------

                                                          The MI Procedure

                                                         Model Information

                                    Data Set                             WORK.ANAL_MONO         
                                    Method                               Monotone               
                                    Number of Imputations                1                      
                                    Seed for random number generator     2079273820             


                                                   Monotone Model Specification
 
                                                Method        Imputed Variables

                                                Regression    SSNRISN BASE WK4 WK12


                                                        Missing Data Patterns
 
                                                                       -----------------------Group Means-----------------------
    Group   trtn   SSNRISN   BASE   WK4   WK12       Freq    Percent        SSNRISN           BASE            WK4           WK12

        1   X      X         X      X     X            27      69.23       1.851852      36.874433      24.299114      15.407407
        2   X      X         X      X     .             9      23.08       1.777778      43.333333      21.000000               
        3   X      X         X      .     .             3       7.69       2.000000      35.000000                              
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------- avisitn=12 trtn=2 ---------------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                           Data Set                  WORK.LSDIFFS_COMPL2
                                           Number of Imputations     20                 


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         5.529882      16.930431      22.736808   291.34       0.342955       0.260433       0.987146


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.986408       4.768313     -12.3711     6.398299   291.34      -9.161478       1.124594

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------------- avisitn=12 trtn=2 ---------------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.63     0.5316
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741435      21.653026      30.831533   214.39       0.423890       0.304160       0.985020


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.653717       5.552615     -13.5984     8.290992   214.39      -6.135295       4.868030

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.48     0.6332
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741447      21.498710      30.677230   212.25       0.426933       0.305708       0.984945


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.860611       5.538703     -13.7785     8.057302   212.25      -6.340681       4.661845

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.52     0.6061
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741462      21.356501      30.535037   210.28       0.429777       0.307149       0.984875


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.067504       5.525852     -13.9607     7.825659   210.28      -6.546067       4.455659

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.56     0.5794
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741480      21.226400      30.404954   208.49       0.432412       0.308479       0.984810


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.274398       5.514069     -14.1449     7.596078   208.49      -6.751453       4.249473

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.59     0.5533
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741502      21.108405      30.286981   206.88       0.434830       0.309695       0.984751


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.481291       5.503361     -14.3312     7.368569   206.88      -6.956839       4.043287

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.63     0.5277
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741526      21.002517      30.181119   205.43       0.437024       0.310795       0.984698


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.688185       5.493735     -14.5195     7.143146   205.43      -7.162225       3.837102

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.67     0.5028
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741553      20.908736      30.087367   204.16       0.438985       0.311775       0.984651


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.895079       5.485195     -14.7100     6.919817   204.16      -7.367611       3.630916

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.71     0.4784
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741584      20.827062      30.005725   203.05       0.440708       0.312634       0.984609


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.101972       5.477748     -14.9025     6.698591   203.05      -7.572997       3.424730

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.75     0.4548
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741618      20.757495      29.936194   202.11       0.442187       0.313370       0.984573


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.308866       5.471398     -15.0972     6.479478   202.11      -7.778383       3.218544

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.79     0.4319
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741654      20.700036      29.878773   201.33       0.443416       0.313980       0.984544


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.515759       5.466148     -15.2940     6.262483   201.33      -7.983769       3.012359

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.83     0.4097
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741694      20.654683      29.833462   200.72       0.444392       0.314464       0.984520


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.722653       5.462002     -15.4929     6.047612   200.72      -8.189155       2.806173

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.86     0.3883
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741737      20.621437      29.800261   200.27       0.445111       0.314820       0.984503


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.929546       5.458962     -15.6940     5.834870   200.27      -8.394541       2.599987

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.90     0.3676
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741783      20.600298      29.779171   199.99       0.445570       0.315047       0.984492


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.136440       5.457029     -15.8971     5.624260   199.99      -8.599927       2.393801

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.94     0.3477
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741833      20.591266      29.770191   199.86       0.445768       0.315145       0.984487


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.343333       5.456207     -16.1025     5.415785   199.86      -8.805313       2.187616

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.98     0.3286
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741885      20.594341      29.773321    199.9       0.445704       0.315114       0.984489


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.550227       5.456493     -16.3099     5.209444    199.9      -9.010700       1.981430

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.02     0.3103
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741940      20.609524      29.788561   200.11       0.445378       0.314953       0.984497


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.757121       5.457890     -16.5195     5.005237   200.11      -9.216086       1.775244

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.05     0.2928
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.741999      20.636813      29.815912   200.47       0.444792       0.314662       0.984511


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.964014       5.460395     -16.7312     4.803164   200.47      -9.421472       1.569059

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.09     0.2760
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.742061      20.676209      29.855373      201       0.443948       0.314244       0.984531


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.170908       5.464007     -16.9450     4.603221      201      -9.626858       1.362873

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.13     0.2601
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.742126      20.727712      29.906944   201.69       0.442848       0.313698       0.984557


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.377801       5.468724     -17.1610     4.405405   201.69      -9.832244       1.156687

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.17     0.2449
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.742193      20.791322      29.970625   202.55       0.441497       0.313027       0.984590


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.584695       5.474543     -17.3791     4.209710   202.55     -10.037630       0.950501

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.20     0.2305
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.742264      20.867039      30.046417   203.57       0.439898       0.312231       0.984628


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.791588       5.481461     -17.5993     4.016131   203.57     -10.243016       0.744316

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-9 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.24     0.2168
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738296      21.363405      30.538615   210.48       0.429483       0.307000       0.984882


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.462501       5.526175     -13.3562     8.431240   210.48      -5.939742       5.060362

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.45     0.6563
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738316      21.209198      30.384431   208.36       0.432606       0.308577       0.984806


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.669395       5.512207     -13.5362     8.197451   208.36      -6.145128       4.854176

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.48     0.6287
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738340      21.067099      30.242356   206.42       0.435525       0.310044       0.984734


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.876289       5.499305     -13.7183     7.965718   206.42      -6.350514       4.647990

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.52     0.6015
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738367      20.937107      30.112392   204.65       0.438231       0.311398       0.984669


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.083182       5.487476     -13.9024     7.736055   204.65      -6.555900       4.441805

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.56     0.5748
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738396      20.819221      29.994538   203.05       0.440714       0.312637       0.984609


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.290076       5.476727     -14.0886     7.508475   203.05      -6.761286       4.235619

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.60     0.5487
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738429      20.713443      29.888794   201.62       0.442966       0.313757       0.984554


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.496969       5.467064     -14.2769     7.282989   201.62      -6.966672       4.029433

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.64     0.5231
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738465      20.619772      29.795160   200.35       0.444980       0.314755       0.984506


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.703863       5.458494     -14.4673     7.059606   200.35      -7.172059       3.823248

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.68     0.4982
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738505      20.538207      29.713637   199.26       0.446749       0.315630       0.984464


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.910756       5.451022     -14.6598     6.838337   199.26      -7.377445       3.617062

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.72     0.4739
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738547      20.468750      29.644224   198.32       0.448267       0.316379       0.984427


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.117650       5.444651     -14.8545     6.619189   198.32      -7.582831       3.410876

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.76     0.4504
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738592      20.411399      29.586921   197.56       0.449529       0.317001       0.984397


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.324544       5.439386     -15.0513     6.402169   197.56      -7.788217       3.204690

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.80     0.4275
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738641      20.366156      29.541729   196.95       0.450530       0.317493       0.984373


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.531437       5.435230     -15.2502     6.187283   196.95      -7.993603       2.998505

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.83     0.4055
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738692      20.333020      29.508647   196.51       0.451267       0.317855       0.984356


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.738331       5.432186     -15.4512     5.974535   196.51      -8.198989       2.792319

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.87     0.3841
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738747      20.311990      29.487675   196.23       0.451737       0.318085       0.984345


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.945224       5.430255     -15.6544     5.763930   196.23      -8.404375       2.586133

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.91     0.3636
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738805      20.303068      29.478813   196.11       0.451939       0.318184       0.984340


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.152118       5.429439     -15.8597     5.555468   196.11      -8.609761       2.379947

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.95     0.3438
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738866      20.306252      29.482062   196.15       0.451871       0.318151       0.984342


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.359011       5.429739     -16.0672     5.349150   196.15      -8.815147       2.173762

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.99     0.3249
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738930      20.321544      29.497420   196.35       0.451534       0.317986       0.984350


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.565905       5.431153     -16.2768     5.144977   196.35      -9.020533       1.967576

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.02     0.3067
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.738997      20.348943      29.524890   196.71       0.450930       0.317689       0.984364


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.772798       5.433681     -16.4885     4.942947   196.71      -9.225919       1.761390

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.06     0.2894
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.739067      20.388448      29.564469   197.24       0.450060       0.317261       0.984385


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.979692       5.437322     -16.7024     4.743057   197.24      -9.431305       1.555204

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.10     0.2728
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.739141      20.440061      29.616159   197.92       0.448927       0.316704       0.984412


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.186586       5.442073     -16.9185     4.545303   197.92      -9.636691       1.349019

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.14     0.2570
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.739217      20.503780      29.679958   198.77       0.447536       0.316018       0.984445


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.393479       5.447932     -17.1366     4.349680   198.77      -9.842077       1.142833

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-8.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.17     0.2420
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.739297      20.579607      29.755869   199.79       0.445891       0.315206       0.984484


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.600373       5.454894     -17.3569     4.156182   199.79     -10.047463       0.936647

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-8.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.21     0.2277
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735184      21.086427      30.258370   206.79       0.434969       0.309765       0.984748


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.271286       5.500761     -13.1160     8.573477   206.79      -5.744190       5.252694

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.41     0.6801
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735213      20.932331      30.104304   204.68       0.438173       0.311369       0.984670


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.478179       5.486739     -13.2960     8.339593   204.68      -5.949576       5.046508

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.45     0.6520
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735245      20.790341      29.962348   202.76       0.441167       0.312862       0.984598


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.685073       5.473787     -13.4779     8.107774   202.76      -6.154962       4.840322

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.49     0.6243
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735280      20.660458      29.832502      201       0.443942       0.314241       0.984531


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.891966       5.461914     -13.6620     7.878034      201      -6.360348       4.634136

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.53     0.5971
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735319      20.542682      29.714766   199.42       0.446489       0.315502       0.984470


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.098860       5.451125     -13.8481     7.650385   199.42      -6.565734       4.427951

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5703
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735360      20.437013      29.609141      198       0.448800       0.316641       0.984415


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.305754       5.441428     -14.0363     7.424838      198      -6.771120       4.221765

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.61     0.5442
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735405      20.343451      29.515626   196.75       0.450866       0.317658       0.984365


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.512647       5.432829     -14.2267     7.201405   196.75      -6.976506       4.015579

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.65     0.5187
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735453      20.261996      29.434221   195.66       0.452681       0.318548       0.984322


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.719541       5.425331     -14.4192     6.980093   195.66      -7.181892       3.809393

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.69     0.4938
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735503      20.192648      29.364927   194.74       0.454239       0.319310       0.984285


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.926434       5.418941     -14.6138     6.760913   194.74      -7.387278       3.603208

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.72     0.4696
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735557      20.135407      29.307742   193.98       0.455533       0.319942       0.984255


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.133328       5.413663     -14.8105     6.543870   193.98      -7.592664       3.397022

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.76     0.4461
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735615      20.090273      29.262668   193.38       0.456559       0.320442       0.984231


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.340221       5.409498     -15.0094     6.328970   193.38      -7.798050       3.190836

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.80     0.4233
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735675      20.057246      29.229705   192.94       0.457314       0.320810       0.984213


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.547115       5.406450     -15.2104     6.116218   192.94      -8.003436       2.984650

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.84     0.4014
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735738      20.036326      29.208851   192.67       0.457795       0.321044       0.984201


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.754009       5.404521     -15.4136     5.905617   192.67      -8.208822       2.778465

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.88     0.3802
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735804      20.027513      29.200108   192.55       0.458000       0.321144       0.984197


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.960902       5.403712     -15.6190     5.697169   192.55      -8.414208       2.572279

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.92     0.3597
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735874      20.030807      29.203475   192.59       0.457928       0.321109       0.984198


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.167796       5.404024     -15.8265     5.490875   192.59      -8.619594       2.366093

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.96     0.3401
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.735947      20.046208      29.218952   192.79       0.457580       0.320940       0.984206


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.374689       5.405456     -16.0361     5.286736   192.79      -8.824980       2.159908

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.99     0.3213
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.736022      20.073716      29.246540   193.15       0.456957       0.320636       0.984221


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.581583       5.408007     -16.2479     5.084748   193.15      -9.030366       1.953722

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.03     0.3033
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.736101      20.113331      29.286238   193.67       0.456061       0.320200       0.984242


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.788476       5.411676     -16.4619     4.884910   193.67      -9.235752       1.747536

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.07     0.2861
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.736183      20.165053      29.338046   194.35       0.454896       0.319631       0.984270


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.995370       5.416461     -16.6780     4.687217   194.35      -9.441138       1.541350

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.11     0.2697
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.736268      20.228882      29.401964    195.2       0.453465       0.318931       0.984304


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.202264       5.422358     -16.8962     4.491665    195.2      -9.646524       1.335165

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.14     0.2541
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.736357      20.304818      29.477993   196.21       0.451773       0.318103       0.984344


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.409157       5.429364     -17.1166     4.298246   196.21      -9.851911       1.128979

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.18     0.2392
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732099      20.822094      29.990798   203.29       0.440335       0.312448       0.984618


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.080070       5.476385     -12.8779     8.717730   203.29      -5.548637       5.445025

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.38     0.7045
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732137      20.668107      29.836850   201.21       0.443618       0.314080       0.984539


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.286964       5.462312     -13.0577     8.483755   201.21      -5.754023       5.238839

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.42     0.6759
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732177      20.526226      29.695012    199.3       0.446686       0.315599       0.984465


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.493857       5.449313     -13.2396     8.251854    199.3      -5.959409       5.032654

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.46     0.6477
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732221      20.396453      29.565285   197.56       0.449531       0.317001       0.984397


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.700751       5.437397     -13.4235     8.022039   197.56      -6.164795       4.826468

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.50     0.6200
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732268      20.278786      29.447668   195.98       0.452142       0.318283       0.984335


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.907644       5.426571     -13.6096     7.794324   195.98      -6.370181       4.620282

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.54     0.5927
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732318      20.173227      29.342161   194.58       0.454510       0.319443       0.984279


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.114538       5.416841     -13.7978     7.568721   194.58      -6.575567       4.414097

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5660
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732372      20.079774      29.248764   193.34       0.456628       0.320476       0.984229


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.321431       5.408213     -13.9881     7.345239   193.34      -6.780953       4.207911

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.61     0.5398
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732428      19.998429      29.167478   192.27       0.458488       0.321381       0.984185


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.528325       5.400692     -14.1805     7.123888   192.27      -6.986339       4.001725

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.65     0.5143
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732487      19.929190      29.098302   191.35       0.460085       0.322156       0.984148


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.735219       5.394284     -14.3751     6.904677   191.35      -7.191725       3.795539

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.69     0.4895
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732550      19.872059      29.041236    190.6       0.461411       0.322798       0.984116


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.942112       5.388992     -14.5718     6.687612    190.6      -7.397111       3.589354

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.73     0.4654
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732616      19.827034      28.996281   190.01       0.462462       0.323307       0.984092


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.149006       5.384819     -14.7707     6.472700   190.01      -7.602497       3.383168

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.77     0.4420
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732684      19.794117      28.963435   189.57       0.463235       0.323680       0.984074


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.355899       5.381769     -14.9717     6.259944   189.57      -7.807883       3.176982

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.81     0.4193
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732756      19.773306      28.942700    189.3       0.463726       0.323917       0.984062


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.562793       5.379842     -15.1749     6.049349    189.3      -8.013270       2.970796

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.85     0.3974
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732831      19.764603      28.934076   189.18       0.463934       0.324018       0.984057


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.769686       5.379040     -15.3803     5.840916   189.18      -8.218656       2.764611

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.89     0.3764
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732910      19.768006      28.937561   189.23       0.463858       0.323981       0.984059


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.976580       5.379364     -15.5878     5.634646   189.23      -8.424042       2.558425

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.93     0.3561
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.732991      19.783517      28.953157   189.43       0.463499       0.323808       0.984068


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.183474       5.380814     -15.7975     5.430539   189.43      -8.629428       2.352239

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.96     0.3366
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.733075      19.811134      28.980863   189.79       0.462857       0.323498       0.984083


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.390367       5.383388     -16.0093     5.228594   189.79      -8.834814       2.146053

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.00     0.3180
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.733163      19.850859      29.020679    190.3       0.461936       0.323053       0.984104


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.597261       5.387084     -16.2233     5.028807    190.3      -9.040200       1.939868

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.04     0.3001
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.733253      19.902690      29.072606   190.98       0.460738       0.322473       0.984132


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.804154       5.391902     -16.4395     4.831174   190.98      -9.245586       1.733682

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.08     0.2831
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.733347      19.966629      29.136643   191.82       0.459267       0.321759       0.984167


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.011048       5.397837     -16.6578     4.635690   191.82      -9.450972       1.527496

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-7.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.11     0.2668
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.733444      20.042674      29.212790   192.82       0.457530       0.320915       0.984208


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.217941       5.404886     -16.8782     4.442349   192.82      -9.656358       1.321311

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-7.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.15     0.2514
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729041      20.570405      29.735898   199.99       0.445567       0.315046       0.984492


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.888854       5.453063     -12.6417     8.864024   199.99      -5.353084       5.637357

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.35     0.7294
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729088      20.416527      29.582069   197.92       0.448928       0.316704       0.984412


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.095748       5.438940     -12.8215     8.629963   197.92      -5.558470       5.431171

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.39     0.7004
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729137      20.274756      29.440350   196.03       0.452069       0.318248       0.984337


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.302642       5.425896     -13.0033     8.397982   196.03      -5.763856       5.224985

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.42     0.6718
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729189      20.145092      29.310741    194.3       0.454982       0.319673       0.984268


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.509535       5.413939     -13.1872     8.168097    194.3      -5.969242       5.018800

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.46     0.6435
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729245      20.027535      29.193242   192.75       0.457655       0.320976       0.984205


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.716429       5.403077     -13.3732     7.940320   192.75      -6.174629       4.812614

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.50     0.6157
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729304      19.922085      29.087854   191.35       0.460081       0.322154       0.984148


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.923322       5.393316     -13.5613     7.714662   191.35      -6.380015       4.606428

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.54     0.5884
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729366      19.828742      28.994575   190.13       0.462250       0.323205       0.984097


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.130216       5.384661     -13.7516     7.491135   190.13      -6.585401       4.400242

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.58     0.5617
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729431      19.747506      28.913408   189.06       0.464155       0.324124       0.984052


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.337109       5.377119     -13.9440     7.269747   189.06      -6.790787       4.194057

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.62     0.5356
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729499      19.678377      28.844350   188.16       0.465789       0.324912       0.984014


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.544003       5.370694     -14.1385     7.050507   188.16      -6.996173       3.987871

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.66     0.5101
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729570      19.621354      28.787403   187.41       0.467147       0.325564       0.983983


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.750897       5.365389     -14.3352     6.833422   187.41      -7.201559       3.781685

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.70     0.4854
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729644      19.576439      28.742566   186.82       0.468222       0.326080       0.983958


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.957790       5.361209     -14.5341     6.618499   186.82      -7.406945       3.575500

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.74     0.4613
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729721      19.543631      28.709839    186.4       0.469013       0.326459       0.983939


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.164684       5.358156     -14.7351     6.405741    186.4      -7.612331       3.369314

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.78     0.4380
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729802      19.522930      28.689222   186.12       0.469514       0.326699       0.983928


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.371577       5.356232     -14.9383     6.195152   186.12      -7.817717       3.163128

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.82     0.4154
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729886      19.514336      28.680716   186.01       0.469725       0.326800       0.983923


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.578471       5.355438     -15.1437     5.986734   186.01      -8.023103       2.956942

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.85     0.3937
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.729972      19.517849      28.684320   186.05       0.469646       0.326762       0.983925


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.785364       5.355774     -15.3512     5.780488   186.05      -8.228489       2.750757

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.89     0.3727
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.730062      19.533469      28.700034   186.25       0.469275       0.326585       0.983933


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.992258       5.357241     -15.5609     5.576414   186.25      -8.433875       2.544571

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.93     0.3526
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.730155      19.561196      28.727859   186.61       0.468615       0.326268       0.983948


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.199151       5.359838     -15.7728     5.374510   186.61      -8.639261       2.338385

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.97     0.3333
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.730251      19.601030      28.767794   187.13       0.467667       0.325814       0.983970


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.406045       5.363562     -15.9869     5.174773   187.13      -8.844647       2.132199

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.01     0.3148
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.730350      19.652971      28.819839    187.8       0.466437       0.325223       0.983999


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.612939       5.368411     -16.2031     4.977199    187.8      -9.050033       1.926014

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.05     0.2971
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.730453      19.717019      28.883994   188.63       0.464927       0.324497       0.984034


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.819832       5.374383     -16.4214     4.781783   188.63      -9.255419       1.719828

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-6.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.08     0.2802
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.730558      19.793174      28.960260   189.63       0.463144       0.323636       0.984076


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -6.026726       5.381474     -16.6420     4.588517   189.63      -9.460805       1.513642

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.12     0.2642
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726011      20.331360      29.493671   196.88       0.450649       0.317551       0.984371


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.697639       5.430808     -12.4077     9.012383   196.88      -5.157532       5.829689

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.31     0.7549
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726066      20.177591      29.339960   194.83       0.454086       0.319236       0.984289


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.904532       5.416637     -12.5873     8.778240   194.83      -5.362918       5.623503

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.35     0.7255
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726124      20.035929      29.198359   192.95       0.457300       0.320803       0.984213


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.111426       5.403551     -12.7690     8.546185   192.95      -5.568304       5.417317

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.39     0.6964
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726185      19.906375      29.068869   191.24       0.460279       0.322251       0.984143


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.318319       5.391555     -12.9529     8.316233   191.24      -5.773690       5.211131

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.43     0.6677
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726249      19.788927      28.951489    189.7       0.463015       0.323574       0.984079


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.525213       5.380659     -13.1388     8.088397    189.7      -5.979076       5.004946

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.47     0.6394
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726316      19.683587      28.846219   188.32       0.465496       0.324771       0.984021


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.732107       5.370868     -13.3269     7.862688   188.32      -6.184462       4.798760

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.51     0.6116
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726387      19.590353      28.753059    187.1       0.467715       0.325837       0.983969


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.939000       5.362188     -13.5171     7.639117    187.1      -6.389848       4.592574

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.55     0.5843
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726460      19.509226      28.672010   186.04       0.469664       0.326771       0.983924


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.145894       5.354625     -13.7095     7.417695   186.04      -6.595234       4.386388

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.59     0.5576
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726537      19.440207      28.603071   185.15       0.471336       0.327570       0.983885


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.352787       5.348184     -13.9040     7.198429   185.15      -6.800620       4.180203

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.63     0.5315
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726617      19.383294      28.546242   184.41       0.472724       0.328232       0.983853


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.559681       5.342868     -14.1007     6.981326   184.41      -7.006006       3.974017

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.67     0.5061
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726700      19.338489      28.501523   183.83       0.473824       0.328756       0.983828


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.766574       5.338682     -14.2995     6.766393   183.83      -7.211392       3.767831

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.71     0.4814
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726786      19.305790      28.468915    183.4       0.474631       0.329140       0.983809


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.973468       5.335627     -14.5006     6.553633    183.4      -7.416778       3.561645

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.74     0.4574
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726875      19.285198      28.448417   183.14       0.475143       0.329383       0.983798


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.180362       5.333706     -14.7038     6.343051   183.14      -7.622164       3.355460

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.78     0.4342
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.726967      19.276714      28.440029   183.02       0.475357       0.329485       0.983793


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.387255       5.332919     -14.9092     6.134649   183.02      -7.827550       3.149274

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.82     0.4118
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.727062      19.280336      28.443751   183.07       0.475273       0.329445       0.983795


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.594149       5.333268     -15.1167     5.928427   183.07      -8.032936       2.943088

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.86     0.3901
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.727161      19.296065      28.459584   183.27       0.474891       0.329264       0.983803


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.801042       5.334752     -15.3265     5.724386   183.27      -8.238322       2.736902

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.90     0.3693
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.727262      19.323902      28.487527   183.62       0.474212       0.328941       0.983819


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.007936       5.337371     -15.5384     5.522522   183.62      -8.443708       2.530717

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.94     0.3493
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.727367      19.363845      28.527581   184.14       0.473239       0.328478       0.983841


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.214829       5.341122     -15.7525     5.322835   184.14      -8.649094       2.324531

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.98     0.3302
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.727475      19.415895      28.579744   184.81       0.471977       0.327876       0.983871


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.421723       5.346003     -15.9688     5.125318   184.81      -8.854481       2.118345

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.01     0.3118
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.727586      19.480053      28.644018   185.63       0.470428       0.327137       0.983906


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.628617       5.352011     -16.1872     4.929967   185.63      -9.059867       1.912160

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.05     0.2943
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.727700      19.556317      28.720402   186.62       0.468600       0.326261       0.983949


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.835510       5.359142     -16.4078     4.736776   186.62      -9.265253       1.705974

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-6 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.09     0.2776
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723008      20.104958      29.264117   193.96       0.455567       0.319959       0.984254


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.506423       5.409632     -12.1757     9.162832   193.96      -4.961979       6.022020

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.28     0.7809
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723072      19.951299      29.110524   191.93       0.459079       0.321668       0.984171


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.713317       5.395417     -12.3552     8.928610   191.93      -5.167365       5.815834

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.32     0.7512
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723138      19.809747      28.969042   190.06       0.462363       0.323259       0.984094


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.920210       5.382290     -12.5369     8.696485   190.06      -5.372751       5.609649

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.36     0.7217
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723208      19.680302      28.839670   188.37       0.465408       0.324728       0.984023


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.127104       5.370258     -12.7207     8.466470   188.37      -5.578137       5.403463

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.40     0.6925
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723281      19.562964      28.722408   186.83       0.468203       0.326071       0.983958


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.333997       5.359329     -12.9066     8.238578   186.83      -5.783523       5.197277

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.44     0.6637
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723356      19.457732      28.617257   185.47       0.470740       0.327285       0.983899


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.540891       5.349510     -13.0946     8.012822   185.47      -5.988909       4.991091

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.47     0.6354
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723436      19.364608      28.524216   184.26       0.473008       0.328368       0.983847


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.747784       5.340807     -13.2848     7.789212   184.26      -6.194295       4.784906

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.51     0.6075
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723518      19.283591      28.443285   183.21       0.474999       0.329315       0.983801


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.954678       5.333225     -13.4771     7.567757   183.21      -6.399681       4.578720

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.55     0.5802
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723603      19.214681      28.374464   182.32       0.476708       0.330126       0.983762


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.161572       5.326769     -13.6716     7.348467   182.32      -6.605067       4.372534

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.59     0.5536
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723691      19.157878      28.317754   181.59       0.478126       0.330798       0.983729


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.368465       5.321443     -13.8683     7.131348   181.59      -6.810453       4.166349

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.63     0.5275
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723783      19.113182      28.273153   181.01       0.479249       0.331329       0.983704


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.575359       5.317251     -14.0671     6.916406   181.01      -7.015840       3.960163

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.67     0.5022
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723877      19.080592      28.240664   180.59       0.480073       0.331718       0.983685


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.782252       5.314195     -14.2682     6.703646   180.59      -7.221226       3.753977

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.71     0.4776
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.723975      19.060110      28.220284   180.33       0.480594       0.331964       0.983673


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.989146       5.312277     -14.4714     6.493072   180.33      -7.426612       3.547791

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.75     0.4537
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724076      19.051735      28.212015   180.22       0.480811       0.332066       0.983668


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.196039       5.311498     -14.6768     6.284686   180.22      -7.631998       3.341606

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.79     0.4306
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724180      19.055467      28.215856   180.27       0.480722       0.332024       0.983670


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.402933       5.311860     -14.8844     6.078488   180.27      -7.837384       3.135420

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.83     0.4083
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724287      19.071306      28.231807   180.46       0.480329       0.331839       0.983679


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.609827       5.313361     -15.0941     5.874479   180.46      -8.042770       2.929234

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.87     0.3868
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724397      19.099252      28.259868   180.82       0.479632       0.331510       0.983695


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.816720       5.316001     -15.3061     5.672656   180.82      -8.248156       2.723048

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.91     0.3661
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724510      19.139304      28.300040   181.33       0.478635       0.331038       0.983718


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.023614       5.319778     -15.5202     5.473016   181.33      -8.453542       2.516863

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.94     0.3463
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724627      19.191464      28.352322   181.99       0.477340       0.330426       0.983747


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.230507       5.324690     -15.7366     5.275556   181.99      -8.658928       2.310677

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.98     0.3273
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724746      19.255731      28.416714   182.82       0.475754       0.329674       0.983784


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.437401       5.330733     -15.9551     5.080269   182.82      -8.864314       2.104491

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-5.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.02     0.3091
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.724869      19.332105      28.493217    183.8       0.473881       0.328783       0.983827


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.644294       5.337904     -16.1757     4.887149    183.8      -9.069700       1.898305

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-5.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.06     0.2917
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720032      19.891201      29.047235   191.23       0.460306       0.322263       0.984142


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.315207       5.389549     -11.9458     9.315392   191.23      -4.766426       6.214352

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.24     0.8075
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720104      19.737651      28.893761   189.21       0.463891       0.323997       0.984058


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.522101       5.375292     -12.1253     9.081098   189.21      -4.971812       6.008166

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.28     0.7774
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720180      19.596209      28.752397   187.36       0.467243       0.325610       0.983980


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.728995       5.362126     -12.3069     8.848907   187.36      -5.177199       5.801980

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.32     0.7475
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720258      19.466873      28.623144   185.67       0.470351       0.327100       0.983908


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.935888       5.350060     -12.4906     8.618833   185.67      -5.382585       5.595795

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.36     0.7179
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720339      19.349644      28.506000   184.15       0.473205       0.328462       0.983842


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.142782       5.339101     -12.6765     8.390889   184.15      -5.587971       5.389609

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.40     0.6886
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720424      19.244522      28.400967    182.8       0.475795       0.329693       0.983783


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.349675       5.329256     -12.8644     8.165088    182.8      -5.793357       5.183423

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.44     0.6598
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720511      19.151508      28.308045    181.6       0.478111       0.330790       0.983730


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.556569       5.320530     -13.0546     7.941441    181.6      -5.998743       4.977237

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.48     0.6314
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720602      19.070600      28.227232   180.56       0.480144       0.331751       0.983683


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.763462       5.312931     -13.2469     7.719957   180.56      -6.204129       4.771052

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.52     0.6036
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720696      19.001799      28.158530   179.68       0.481888       0.332573       0.983643


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.970356       5.306461     -13.4414     7.500644   179.68      -6.409515       4.564866

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.56     0.5763
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720793      18.945105      28.101938   178.95       0.483335       0.333254       0.983610


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.177250       5.301126     -13.6380     7.283511   178.95      -6.614901       4.358680

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.60     0.5497
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720893      18.900519      28.057456   178.38       0.484481       0.333792       0.983584


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.384143       5.296929     -13.8368     7.068562   178.38      -6.820287       4.152494

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.64     0.5237
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.720996      18.868039      28.025085   177.97       0.485320       0.334185       0.983565


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.591037       5.293872     -14.0379     6.855804   177.97      -7.025673       3.946309

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.68     0.4984
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721102      18.847666      28.004824    177.7       0.485851       0.334434       0.983553


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.797930       5.291958     -14.2411     6.645238    177.7      -7.231059       3.740123

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.72     0.4739
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721212      18.839401      27.996673    177.6       0.486070       0.334536       0.983548


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.004824       5.291188     -14.4465     6.436868    177.6      -7.436445       3.533937

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.76     0.4501
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721324      18.843242      28.000632   177.64       0.485977       0.334493       0.983550


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.211717       5.291562     -14.6541     6.230695   177.64      -7.641831       3.327752

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.80     0.4271
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721440      18.859190      28.016702   177.84       0.485573       0.334304       0.983560


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.418611       5.293081     -14.8639     6.026717   177.84      -7.847217       3.121566

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.83     0.4050
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721559      18.887245      28.044882   178.19       0.484858       0.333969       0.983576


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.625504       5.295742     -15.0759     5.824933   178.19      -8.052603       2.915380

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.87     0.3836
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721681      18.927408      28.085172    178.7       0.483836       0.333489       0.983599


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.832398       5.299545     -15.2901     5.625341    178.7      -8.257989       2.709194

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.91     0.3631
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721806      18.979677      28.137573   179.36       0.482511       0.332866       0.983629


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.039292       5.304486     -15.5065     5.427935   179.36      -8.463375       2.503009

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.95     0.3434
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.721934      19.044053      28.202083   180.18       0.480887       0.332102       0.983666


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.246185       5.310563     -15.7251     5.232710   180.18      -8.668761       2.296823

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.99     0.3245
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.722065      19.120536      28.278704   181.16       0.478970       0.331197       0.983710


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.453079       5.317773     -15.9458     5.039660   181.16      -8.874147       2.090637

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -1.03     0.3065
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717084      19.690088      28.843026   188.67       0.464850       0.324459       0.984036


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.123992       5.370570     -11.7181     9.470087   188.67      -4.570874       6.406683

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.21     0.8344
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717165      19.536647      28.689670   186.67       0.468505       0.326216       0.983951


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.330885       5.356274     -11.8975     9.235724   186.67      -4.776260       6.200498

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.25     0.8040
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717248      19.395314      28.548425   184.83       0.471924       0.327851       0.983872


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.537779       5.343073     -12.0790     9.003471   184.83      -4.981646       5.994312

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.29     0.7738
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717335      19.266088      28.419290   183.16       0.475094       0.329360       0.983799


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.744672       5.330975     -12.2627     8.773342   183.16      -5.187032       5.788126

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.33     0.7438
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717425      19.148969      28.302265   181.65       0.478005       0.330740       0.983732


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.951566       5.319987     -12.4485     8.545351   181.65      -5.392418       5.581941

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.37     0.7142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717518      19.043956      28.197351    180.3       0.480646       0.331988       0.983672


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.158460       5.310118     -12.6364     8.319509    180.3      -5.597804       5.375755

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.41     0.6849
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717615      18.951051      28.104546   179.12       0.483007       0.333100       0.983618


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.365353       5.301372     -12.8265     8.095827   179.12      -5.803190       5.169569

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.45     0.6560
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717714      18.870253      28.023852   178.08       0.485081       0.334073       0.983571


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.572247       5.293756     -13.0188     7.874316   178.08      -6.008576       4.963383

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.49     0.6276
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717816      18.801561      27.955269   177.21       0.486859       0.334905       0.983531


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.779140       5.287274     -13.2133     7.654984   177.21      -6.213962       4.757198

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.53     0.5998
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.717922      18.744977      27.898795   176.49       0.488334       0.335595       0.983497


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.986034       5.281931     -13.4099     7.437838   176.49      -6.419348       4.551012

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5726
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718031      18.700500      27.854432   175.92       0.489502       0.336139       0.983471


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.192927       5.277730     -13.6087     7.222885   175.92      -6.624734       4.344826

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.60     0.5460
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718142      18.668130      27.822179   175.51       0.490357       0.336537       0.983452


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.399821       5.274673     -13.8098     7.010128   175.51      -6.830120       4.138640

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.64     0.5201
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718257      18.647866      27.802036   175.25       0.490896       0.336788       0.983439


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.606715       5.272764     -14.0130     6.799572   175.25      -7.035506       3.932455

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.68     0.4949
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718375      18.639710      27.794004   175.15       0.491118       0.336891       0.983434


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.813608       5.272002     -14.2184     6.591219   175.15      -7.240892       3.726269

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.72     0.4704
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718496      18.643661      27.798082   175.19       0.491021       0.336846       0.983437


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.020502       5.272389     -14.4261     6.385070   175.19      -7.446278       3.520083

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.76     0.4468
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718621      18.659718      27.814270   175.39       0.490605       0.336653       0.983446


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.227395       5.273924     -14.6359     6.181123   175.39      -7.651664       3.313897

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.80     0.4239
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718748      18.687883      27.842568   175.75       0.489873       0.336312       0.983462


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.434289       5.276606     -14.8480     5.979378   175.75      -7.857051       3.107712

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.84     0.4018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.718878      18.728155      27.882977   176.25       0.488827       0.335824       0.983486


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.641182       5.280433     -15.0622     5.779832   176.25      -8.062437       2.901526

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.88     0.3806
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.719012      18.780534      27.935496   176.91       0.487471       0.335191       0.983517


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.848076       5.285404     -15.2786     5.582479   176.91      -8.267823       2.695340

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.92     0.3603
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.719149      18.845019      28.000125   177.72       0.485810       0.334415       0.983554


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.054970       5.291514     -15.4973     5.387315   177.72      -8.473209       2.489154

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-4.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.96     0.3407
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.719288      18.921612      28.076865   178.69       0.483852       0.333496       0.983599


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.261863       5.298761     -15.7181     5.194332   178.69      -8.678595       2.282969

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-4.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.99     0.3220
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714163      19.501618      28.651489    186.3       0.469185       0.326542       0.983935


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.932776       5.352709     -11.4925     9.626936    186.3      -4.375321       6.599015

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.17     0.8618
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714252      19.348287      28.498252   184.31       0.472908       0.328320       0.983849


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.139670       5.338375     -11.6718     9.392510   184.31      -4.580707       6.392829

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.21     0.8312
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714345      19.207064      28.357125   182.49       0.476390       0.329976       0.983769


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.346563       5.325141     -11.8533     9.160200   182.49      -4.786093       6.186644

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.25     0.8007
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714440      19.077947      28.228109   180.83       0.479620       0.331504       0.983695


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.553457       5.313013     -12.0369     8.930021   180.83      -4.991479       5.980458

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.29     0.7703
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714539      18.960937      28.111203   179.33       0.482585       0.332901       0.983627


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.760350       5.302000     -12.2227     8.701985   179.33      -5.196865       5.774272

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.33     0.7403
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714640      18.856034      28.006406   177.99       0.485276       0.334164       0.983566


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.967244       5.292108     -12.4106     8.476106   177.99      -5.402251       5.568086

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.37     0.7105
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714745      18.763238      27.913721   176.81       0.487681       0.335290       0.983512


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.174137       5.283344     -12.6007     8.252393   176.81      -5.607637       5.361901

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.41     0.6812
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714853      18.682550      27.833145   175.78       0.489794       0.336275       0.983464


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.381031       5.275713     -12.7929     8.030858   175.78      -5.813023       5.155715

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.45     0.6523
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.714964      18.613968      27.764680   174.92       0.491605       0.337117       0.983424


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.587925       5.269220     -12.9874     7.811509   174.92      -6.018410       4.949529

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.49     0.6239
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715078      18.557493      27.708325    174.2       0.493107       0.337815       0.983390


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.794818       5.263870     -13.1840     7.594352    174.2      -6.223796       4.743343

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.53     0.5961
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715195      18.513125      27.664080   173.64       0.494296       0.338365       0.983363


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.001712       5.259665     -13.3828     7.379395   173.64      -6.429182       4.537158

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5689
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715316      18.480864      27.631946   173.23       0.495165       0.338768       0.983344


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.208605       5.256610     -13.5839     7.166642   173.23      -6.634568       4.330972

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.61     0.5424
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715439      18.460710      27.611922   172.98       0.495713       0.339021       0.983332


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.415499       5.254705     -13.7871     6.956096   172.98      -6.839954       4.124786

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.65     0.5166
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715566      18.452663      27.604008   172.87       0.495936       0.339124       0.983327


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.622392       5.253952     -13.9925     6.747760   172.87      -7.045340       3.918601

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.69     0.4915
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715696      18.456724      27.608204   172.92       0.495835       0.339077       0.983329


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.829286       5.254351     -14.2002     6.541635   172.92      -7.250726       3.712415

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.73     0.4671
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715828      18.472891      27.624511   173.12       0.495408       0.338880       0.983338


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.036180       5.255902     -14.4101     6.337719   173.12      -7.456112       3.506229

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.77     0.4436
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.715964      18.501165      27.652927   173.47       0.494659       0.338533       0.983355


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.243073       5.258605     -14.6222     6.136012   173.47      -7.661498       3.300043

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.81     0.4208
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.716103      18.541546      27.693455   173.97       0.493589       0.338038       0.983379


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.449967       5.262457     -14.8364     5.936511   173.97      -7.866884       3.093858

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.85     0.3989
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.716246      18.594034      27.746092   174.63       0.492204       0.337396       0.983410


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.656860       5.267456     -15.0529     5.739210   174.63      -8.072270       2.887672

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.88     0.3779
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.716391      18.658629      27.810840   175.44       0.490508       0.336608       0.983448


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.863754       5.273598     -15.2716     5.544104   175.44      -8.277656       2.681486

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-3.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.92     0.3576
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.716539      18.735331      27.887698   176.41       0.488508       0.335676       0.983493


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -5.070647       5.280880     -15.4925     5.351186   176.41      -8.483042       2.475300

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.96     0.3383
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711269      19.325793      28.472626   184.11       0.473297       0.328505       0.983840


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.741560       5.335975     -11.2691     9.785960   184.11      -4.179769       6.791347

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.14     0.8896
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711367      19.172572      28.319507   182.13       0.477084       0.330305       0.983753


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.948454       5.321608     -11.4484     9.551476   182.13      -4.385155       6.585161

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.18     0.8587
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711468      19.031457      28.178499   180.31       0.480627       0.331979       0.983672


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.155348       5.308342     -11.6298     9.319114   180.31      -4.590541       6.378975

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.22     0.8279
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711572      18.902450      28.049600   178.66       0.483913       0.333525       0.983597


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.362241       5.296187     -11.8134     9.088888   178.66      -4.795927       6.172790

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.26     0.7973
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711679      18.785549      27.932813   177.17       0.486931       0.334939       0.983529


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.569135       5.285150     -11.9991     8.860812   177.17      -5.001313       5.966604

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.30     0.7669
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711789      18.680756      27.828135   175.84       0.489669       0.336217       0.983467


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.776028       5.275238     -12.1870     8.634899   175.84      -5.206699       5.760418

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.34     0.7368
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711903      18.588070      27.735568   174.67       0.492117       0.337355       0.983412


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.982922       5.266457     -12.3770     8.411159   174.67      -5.412085       5.554232

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.38     0.7070
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712019      18.507490      27.655111   173.66       0.494266       0.338352       0.983364


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.189815       5.258813     -12.5692     8.189602   173.66      -5.617471       5.348047

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.42     0.6776
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712139      18.439018      27.586764   172.79       0.496108       0.339203       0.983323


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.396709       5.252310     -12.7637     7.970238   172.79      -5.822857       5.141861

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.46     0.6487
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712262      18.382653      27.530527   172.08       0.497636       0.339909       0.983289


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.603603       5.246954     -12.9603     7.753073   172.08      -6.028243       4.935675

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.50     0.6204
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712388      18.338394      27.486401   171.53       0.498844       0.340465       0.983262


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.810496       5.242747     -13.1591     7.538114   171.53      -6.233629       4.729489

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.54     0.5926
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712517      18.306243      27.454385   171.12       0.499728       0.340871       0.983242


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.017390       5.239693     -13.3601     7.325365   171.12      -6.439015       4.523304

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.58     0.5655
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712649      18.286198      27.434479   170.87       0.500283       0.341126       0.983230


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.224283       5.237793     -13.5634     7.114831   170.87      -6.644401       4.317118

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.62     0.5390
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712784      18.278261      27.426684   170.77       0.500508       0.341230       0.983225


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.431177       5.237049     -13.7689     6.906512   170.77      -6.849787       4.110932

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.66     0.5132
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.712922      18.282430      27.430999   170.82       0.500402       0.341181       0.983227


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.638070       5.237461     -13.9766     6.700411   170.82      -7.055173       3.904746

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.69     0.4882
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.713064      18.298707      27.447424   171.02       0.499965       0.340980       0.983237


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.844964       5.239029     -14.1865     6.496526   171.02      -7.260559       3.698561

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.73     0.4640
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.713208      18.327091      27.475959   171.37       0.499199       0.340628       0.983254


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.051857       5.241752     -14.3986     6.294856   171.37      -7.465945       3.492375

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.77     0.4406
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.713356      18.367581      27.516605   171.87       0.498107       0.340125       0.983278


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.258751       5.245627     -14.6129     6.095398   171.87      -7.671331       3.286189

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.81     0.4180
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.713506      18.420179      27.569361   172.52       0.496693       0.339474       0.983310


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.465645       5.250653     -14.8294     5.898147   172.52      -7.876717       3.080004

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.85     0.3962
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.713660      18.484883      27.634227   173.33       0.494964       0.338675       0.983348


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.672538       5.256827     -15.0482     5.703097   173.33      -8.082103       2.873818

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.89     0.3753
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.713817      18.561695      27.711203   174.29       0.492924       0.337730       0.983394


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.879432       5.264143     -15.2691     5.510242   174.29      -8.287489       2.667632

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=-3 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.93     0.3553
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708403      19.162612      28.306434   182.08       0.477170       0.330345       0.983751


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.550345       5.320379     -11.0479     9.947179   182.08      -3.984216       6.983678

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.10     0.9177
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708509      19.009500      28.153434   180.12       0.481019       0.332164       0.983663


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.757238       5.305981     -11.2271     9.712642   180.12      -4.189602       6.777493

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.14     0.8867
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708619      18.868495      28.012544   178.31       0.484620       0.333857       0.983581


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.964132       5.292688     -11.4085     9.480232   178.31      -4.394988       6.571307

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.18     0.8557
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708731      18.739597      27.883765   176.67       0.487960       0.335420       0.983506


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.171025       5.280508     -11.5920     9.249964   176.67      -4.600374       6.365121

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.22     0.8248
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708847      18.622806      27.767095   175.19       0.491026       0.336849       0.983437


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.377919       5.269449     -11.7777     9.021852   175.19      -4.805760       6.158935

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.26     0.7940
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708966      18.518122      27.662536   173.87       0.493809       0.338140       0.983374


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.584813       5.259519     -11.9655     8.795908   173.87      -5.011146       5.952750

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.30     0.7635
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.709088      18.425545      27.570087   172.71       0.496297       0.339291       0.983318


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.791706       5.250723     -12.1556     8.572144   172.71      -5.216532       5.746564

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.34     0.7333
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.709213      18.345075      27.489749    171.7       0.498481       0.340298       0.983270


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.998600       5.243067     -12.3478     8.350569    171.7      -5.421918       5.540378

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.38     0.7035
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.709341      18.276712      27.421520   170.84       0.500353       0.341158       0.983228


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.205493       5.236556     -12.5422     8.131192   170.84      -5.627304       5.334193

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.42     0.6742
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.709473      18.220456      27.365402   170.14       0.501905       0.341870       0.983194


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.412387       5.231195     -12.7388     7.914021   170.14      -5.832690       5.128007

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.46     0.6453
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.709607      18.176307      27.321395   169.58       0.503132       0.342432       0.983167


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.619280       5.226987     -12.9376     7.699061   169.58      -6.038076       4.921821

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.50     0.6169
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.709745      18.144265      27.289497   169.18       0.504029       0.342842       0.983147


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.826174       5.223935     -13.1387     7.486318   169.18      -6.243462       4.715635

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.54     0.5892
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.709885      18.124330      27.269710   168.93       0.504591       0.343099       0.983134


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.033068       5.222041     -13.3419     7.275796   168.93      -6.448848       4.509450

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.58     0.5621
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.710029      18.116502      27.262033   168.83       0.504818       0.343202       0.983129


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.239961       5.221306     -13.5474     7.067495   168.83      -6.654234       4.303264

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.62     0.5357
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.710176      18.120781      27.266466   168.88       0.504707       0.343152       0.983132


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.446855       5.221730     -13.7551     6.861418   168.88      -6.859621       4.097078

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.66     0.5101
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.710326      18.137167      27.283010   169.08       0.504260       0.342948       0.983142


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.653748       5.223314     -13.9651     6.657563   169.08      -7.065007       3.890892

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.70     0.4852
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.710479      18.165660      27.311663   169.43       0.503478       0.342590       0.983159


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.860642       5.226056     -14.1772     6.455930   169.43      -7.270393       3.684707

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.74     0.4611
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.710635      18.206260      27.352428   169.93       0.502364       0.342080       0.983184


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.067535       5.229955     -14.3916     6.256514   169.93      -7.476118       3.478521

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.78     0.4378
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.710795      18.258967      27.405302   170.58       0.500923       0.341420       0.983216


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.274429       5.235007     -14.6082     6.059311   170.58      -7.683277       3.272335

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.82     0.4153
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.710957      18.323781      27.470287   171.38       0.499160       0.340610       0.983255


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.481323       5.241210     -14.8270     5.864316   171.38      -7.890435       3.066149

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-2.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.86     0.3937
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.711123      18.400703      27.547381   172.34       0.497083       0.339653       0.983301


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.688216       5.248560     -15.0480     5.671520   172.34      -8.097593       2.859964

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-2.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.89     0.3730
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705564      19.012074      28.152916   180.23       0.480791       0.332057       0.983668


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.359129       5.305932     -10.8289     10.11061   180.23      -3.788663       7.176010

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.07     0.9461
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705679      18.859072      28.000034   178.27       0.484698       0.333894       0.983579


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.566023       5.291506     -11.0081     9.876024   178.27      -3.994049       6.969824

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.11     0.9149
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705797      18.718176      27.859263   176.48       0.488353       0.335604       0.983497


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.772916       5.278187     -11.1894     9.643572   176.48      -4.199435       6.763639

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.15     0.8837
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705918      18.589388      27.730602   174.85       0.491744       0.337182       0.983420


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.979810       5.265985     -11.3729     9.413267   174.85      -4.404821       6.557453

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.19     0.8526
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.706042      18.472706      27.614051   173.38       0.494857       0.338625       0.983351


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.186703       5.254907     -11.5585     9.185123   173.38      -4.610207       6.351267

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.23     0.8216
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.706170      18.368132      27.509610   172.06       0.497681       0.339929       0.983288


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.393597       5.244960     -11.7463     8.959152   172.06      -4.815593       6.145081

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.27     0.7908
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.706300      18.275664      27.417280   170.91       0.500207       0.341091       0.983231


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.600490       5.236151     -11.9363     8.735367   170.91      -5.020980       5.938896

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.31     0.7602
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.706434      18.195304      27.337060    169.9       0.502424       0.342108       0.983182


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.807384       5.228485     -12.1285     8.513776    169.9      -5.226366       5.732710

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.35     0.7300
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.706571      18.127050      27.268950   169.05       0.504324       0.342977       0.983140


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.014278       5.221968     -12.3229     8.294389   169.05      -5.431752       5.526524

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.39     0.7002
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.706711      18.070904      27.212950   168.35       0.505899       0.343695       0.983106


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.221171       5.216603     -12.5196     8.077214   168.35      -5.637138       5.320338

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.43     0.6708
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.706854      18.026864      27.169061    167.8       0.507143       0.344262       0.983078


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.428065       5.212395     -12.7184     7.862255    167.8      -5.842524       5.114153

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.47     0.6419
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.707000      17.994932      27.137282   167.41       0.508051       0.344675       0.983058


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.634958       5.209346     -12.9194     7.649519   167.41      -6.047910       4.907967

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.51     0.6137
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.707149      17.975106      27.117613   167.16       0.508620       0.344934       0.983046


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.841852       5.207457     -13.1227     7.439009   167.16      -6.253296       4.701781

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.55     0.5860
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.707302      17.967388      27.110054   167.06       0.508848       0.345037       0.983041


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.048745       5.206732     -13.3282     7.230727   167.06      -6.458682       4.495595

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.59     0.5590
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.707457      17.971776      27.114606   167.11       0.508733       0.344985       0.983043


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.255639       5.207169     -13.5360     7.024674   167.11      -6.664903       4.289410

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.63     0.5327
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.707616      17.988272      27.131268   167.31       0.508275       0.344777       0.983053


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.462533       5.208768     -13.7459     6.820849   167.31      -6.872061       4.083224

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.66     0.5071
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.707777      18.016874      27.160041   167.66       0.507478       0.344415       0.983071


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.669426       5.211530     -13.9581     6.619251   167.66      -7.079219       3.877038

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.70     0.4823
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.707942      18.057584      27.200923   168.16       0.506343       0.343898       0.983096


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.876320       5.215450     -14.1725     6.419876   168.16      -7.286377       3.670853

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.74     0.4584
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708110      18.110400      27.253916    168.8       0.504877       0.343229       0.983128


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.083213       5.220528     -14.3891     6.222720    168.8      -7.493536       3.464667

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.78     0.4352
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708281      18.175324      27.319019   169.61       0.503083       0.342410       0.983168


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.290107       5.226760     -14.6080     6.027776   169.61      -7.700694       3.258481

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.82     0.4129
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.708455      18.252354      27.396232   170.56       0.500970       0.341441       0.983214


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.497000       5.234141     -14.8290     5.835039   170.56      -7.907852       3.052295

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.86     0.3915
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.702752      18.874181      28.012070   178.55       0.484148       0.333635       0.983592


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.167913       5.292643     -10.6121     10.27627   178.55      -3.593111       7.368342

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.03     0.9747
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.702875      18.721288      27.859307    176.6       0.488108       0.335489       0.983502


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.374807       5.278192     -10.7913     10.04164    176.6      -3.798497       7.162156

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.07     0.9435
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703002      18.580502      27.718654   174.82       0.491814       0.337215       0.983419


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.581701       5.264851     -10.9726     9.809151   174.82      -4.003883       6.955970

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.11     0.9121
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703132      18.451823      27.590111   173.19       0.495251       0.338808       0.983342


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.788594       5.252629     -11.1560     9.578813   173.19      -4.209269       6.749784

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.15     0.8808
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703265      18.335251      27.473679   171.73       0.498408       0.340264       0.983271


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.995488       5.241534     -11.3416     9.350641   171.73      -4.414655       6.543599

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.19     0.8496
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703401      18.230786      27.369357   170.42       0.501271       0.341580       0.983208


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.202381       5.231573     -11.5294     9.124648   170.42      -4.620041       6.337413

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.23     0.8185
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703540      18.138428      27.277145   169.27       0.503832       0.342752       0.983151


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.409275       5.222753     -11.7194     8.900845   169.27      -4.825427       6.131227

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.27     0.7876
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703682      18.058177      27.197043   168.27       0.506079       0.343778       0.983102


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.616168       5.215078     -11.9116     8.679241   168.27      -5.030813       5.925042

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.31     0.7570
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703828      17.990033      27.129052   167.43       0.508005       0.344654       0.983059


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.823062       5.208556     -12.1060     8.459847   167.43      -5.236199       5.718856

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.35     0.7268
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703976      17.933995      27.073171   166.73       0.509601       0.345379       0.983024


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.029956       5.203188     -12.3026     8.242669   166.73      -5.441585       5.512670

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.39     0.6969
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.704128      17.890065      27.029400   166.19       0.510861       0.345950       0.982997


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.236849       5.198981     -12.5014     8.027714   166.19      -5.646971       5.306484

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.43     0.6676
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.704283      17.858242      26.997739   165.79       0.511780       0.346366       0.982977


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.443743       5.195935     -12.7025     7.814986   165.79      -5.853687       5.100299

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.47     0.6387
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.704440      17.838526      26.978189   165.55       0.512355       0.346626       0.982964


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.650636       5.194053     -12.9058     7.604490   165.55      -6.060845       4.894113

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.51     0.6105
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.704601      17.830917      26.970749   165.45       0.512583       0.346729       0.982959


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.857530       5.193337     -13.1113     7.396226   165.45      -6.268004       4.687927

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.55     0.5829
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.704766      17.835415      26.975419    165.5       0.512464       0.346675       0.982962


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.064423       5.193787     -13.3190     7.190197    165.5      -6.475162       4.481741

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.59     0.5560
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.704933      17.852020      26.992199    165.7       0.511997       0.346464       0.982972


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.271317       5.195402     -13.5290     6.986402    165.7      -6.682320       4.275556

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.63     0.5298
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705103      17.880732      27.021090   166.05       0.511185       0.346097       0.982990


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.478210       5.198181     -13.7413     6.784838   166.05      -6.889478       4.069370

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.67     0.5043
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705276      17.921551      27.062091   166.55       0.510031       0.345574       0.983015


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.685104       5.202124     -13.9557     6.585502   166.55      -7.096637       3.863184

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.71     0.4797
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705453      17.974477      27.115202   167.19       0.508539       0.344897       0.983047


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.891998       5.207226     -14.1724     6.388391   167.19      -7.303795       3.656998

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.75     0.4559
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705633      18.039510      27.180424   167.99       0.506716       0.344068       0.983088


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.098891       5.213485     -14.3913     6.193497   167.99      -7.510953       3.450813

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-1.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.79     0.4329
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.705815      18.116650      27.257756   168.94       0.504569       0.343089       0.983135


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.305785       5.220896     -14.6124     6.000814   168.94      -7.718111       3.244627

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-1.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.82     0.4107
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.699967      18.748932      27.883897   177.03       0.487226       0.335077       0.983522


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.023302       5.280521     -10.3976     10.44417   177.03      -3.397558       7.560673

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=-9 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.00     0.9965
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700099      18.596148      27.731252   175.09       0.491236       0.336946       0.983432


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.183591       5.266047     -10.5767     10.20951   175.09      -3.602944       7.354488

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-8.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.03     0.9722
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700235      18.455471      27.590718   173.32       0.494989       0.338686       0.983348


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.390485       5.252687     -10.7580     9.976984   173.32      -3.808330       7.148302

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-7.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.07     0.9408
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700373      18.326902      27.462293    171.7       0.498469       0.340292       0.983270


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.597378       5.240448     -10.9414     9.746618    171.7      -4.013716       6.942116

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-7.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.11     0.9094
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700515      18.210439      27.345979   170.24       0.501665       0.341760       0.983199


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.804272       5.229338     -11.1270     9.518423   170.24      -4.219102       6.735930

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-6.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.15     0.8779
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700659      18.106084      27.241776   168.94       0.504565       0.343087       0.983135


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.011166       5.219365     -11.3147     9.292411   168.94      -4.424488       6.529745

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=-6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.19     0.8466
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700807      18.013835      27.149682    167.8       0.507157       0.344269       0.983078


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.218059       5.210536     -11.5047     9.068593    167.8      -4.629874       6.323559

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-5.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.23     0.8154
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700958      17.933693      27.069699    166.8       0.509432       0.345302       0.983028


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.424953       5.202855     -11.6969     8.846980    166.8      -4.835313       6.117373

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-4.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.27     0.7845
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.701112      17.865659      27.001826   165.96       0.511382       0.346186       0.982985


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.631846       5.196328     -11.8913     8.627581   165.96      -5.042471       5.911187

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-4.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.31     0.7539
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.701269      17.809731      26.946064   165.27       0.512997       0.346916       0.982950


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.838740       5.190960     -12.0879     8.410403   165.27      -5.249630       5.705002

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-3.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.35     0.7236
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.701429      17.765910      26.902411   164.73       0.514271       0.347491       0.982922


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.045633       5.186753     -12.2867     8.195453   164.73      -5.456788       5.498816

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=-3 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.39     0.6938
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.701593      17.734197      26.870869   164.34       0.515201       0.347909       0.982902


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.252527       5.183712     -12.4878     7.982734   164.34      -5.663946       5.292630

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-2.4 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.43     0.6645
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.701759      17.714590      26.851437    164.1       0.515781       0.348170       0.982889


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.459421       5.181837     -12.6911     7.772252    164.1      -5.871104       5.086445

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-1.8 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.47     0.6357
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.701929      17.707091      26.844116      164       0.516009       0.348273       0.982884


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.666314       5.181131     -12.8966     7.564008      164      -6.078263       4.880259

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-1.2 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.51     0.6075
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.702101      17.711698      26.848904   164.05       0.515885       0.348217       0.982887


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.873208       5.181593     -13.1044     7.358003   164.05      -6.285421       4.674073

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=-0.6 ------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.55     0.5800
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.702277      17.728412      26.865803   164.25       0.515409       0.348003       0.982897


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.080101       5.183223     -13.3144     7.154236   164.25      -6.492579       4.467887

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.59     0.5532
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.702456      17.757234      26.894812    164.6       0.514583       0.347631       0.982915


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.286995       5.186021     -13.5267     6.952706    164.6      -6.699737       4.261702

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.63     0.5271
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.702638      17.798162      26.935932    165.1       0.513411       0.347103       0.982941


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.493888       5.189984     -13.7412     6.753408    165.1      -6.906896       4.055516

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.67     0.5018
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.702823      17.851197      26.989162   165.74       0.511896       0.346418       0.982974


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.700782       5.195109     -13.9579     6.556340   165.74      -7.114054       3.849330

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.71     0.4772
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703011      17.916340      27.054502   166.54       0.510046       0.345581       0.983014


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.907676       5.201394     -14.1768     6.361494   166.54      -7.321212       3.643144

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=-0.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.75     0.4535
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.703203      17.993589      27.131952   167.49       0.507868       0.344592       0.983062


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -4.114569       5.208834     -14.3980     6.168863   167.49      -7.528371       3.436959

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=-0.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.79     0.4307
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-9 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697210      18.636326      27.768396   175.68       0.490015       0.336378       0.983459


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.214518       5.269573     -10.1853     10.61433   175.68      -3.202005       7.753005

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-9 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.04     0.9676
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-8.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697351      18.483652      27.615870   173.75       0.494070       0.338261       0.983368


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.007624       5.255080     -10.3644     10.37964   173.75      -3.407391       7.546819

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-8.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.00     0.9988
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-7.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697494      18.343085      27.475454   171.98       0.497864       0.340014       0.983284


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.199269       5.241703     -10.5456     10.14709   171.98      -3.612777       7.340633

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-7.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.04     0.9697
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-7.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697641      18.214625      27.347148   170.37       0.501384       0.341631       0.983205


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.406163       5.229450     -10.7290     9.916698   170.37      -3.818163       7.134448

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-7.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.08     0.9382
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-6.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697792      18.098272      27.230953   168.92       0.504616       0.343110       0.983134


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.613056       5.218329     -10.9146     9.688483   168.92      -4.024097       6.928262

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-6.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.12     0.9066
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-6 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697945      17.994025      27.126868   167.63       0.507549       0.344447       0.983069


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.819950       5.208346     -11.1024     9.462456   167.63      -4.231256       6.722076

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-6 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.16     0.8751
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-5.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.698101      17.901886      27.034893   166.49       0.510170       0.345637       0.983012


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.026843       5.199509     -11.2923     9.238628   166.49      -4.438414       6.515891

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-5.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.20     0.8437
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-4.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.698261      17.821854      26.955028    165.5       0.512470       0.346678       0.982961


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.233737       5.191823     -11.4845     9.017008    165.5      -4.645572       6.309705

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-4.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.24     0.8125
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-4.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.698423      17.753929      26.887273   164.66       0.514441       0.347567       0.982918


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.440631       5.185294     -11.6789     8.797607   164.66      -4.852730       6.103519

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-4.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.28     0.7815
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-3.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.698589      17.698111      26.831629   163.97       0.516073       0.348302       0.982883


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.647524       5.179926     -11.8755     8.580431   163.97      -5.059889       5.897333

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-3.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.32     0.7508
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.698758      17.654400      26.788095   163.43       0.517361       0.348880       0.982855


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.854418       5.175722     -12.0743     8.365487   163.43      -5.267047       5.691148

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.36     0.7206
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.698930      17.622795      26.756672   163.05       0.518299       0.349301       0.982835


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.061311       5.172685     -12.2754     8.152779   163.05      -5.474205       5.484962

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.40     0.6908
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.699105      17.603298      26.737358    162.8       0.518883       0.349563       0.982822


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.268205       5.170818     -12.4787     7.942312    162.8      -5.681364       5.278776

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.44     0.6615
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.699283      17.595908      26.730155   162.71       0.519112       0.349666       0.982817


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.475098       5.170121     -12.6843     7.734087   162.71      -5.888522       5.072590

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.48     0.6328
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.699464      17.600625      26.735062   162.76       0.518984       0.349608       0.982820


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.681992       5.170596     -12.8921     7.528106   162.76      -6.095680       4.866405

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=-0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.52     0.6047
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.699649      17.617449      26.752080   162.96       0.518499       0.349391       0.982830


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.888886       5.172241     -13.1021     7.324367   162.96      -6.302838       4.660219

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.56     0.5772
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.699836      17.646379      26.781207   163.31       0.517660       0.349015       0.982849


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.095779       5.175056     -13.3144     7.122869   163.31      -6.509997       4.454033

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.60     0.5505
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700027      17.687417      26.822445   163.81       0.516470       0.348481       0.982874


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.302673       5.179039     -13.5290     6.923609   163.81      -6.717155       4.247847

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.64     0.5246
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700221      17.740562      26.875794   164.45       0.514935       0.347790       0.982908


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.509566       5.184187     -13.7457     6.726581   164.45      -6.924313       4.041662

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.68     0.4994
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700417      17.805814      26.941252   165.25       0.513059       0.346944       0.982949


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.716460       5.190496     -13.9647     6.531780   165.25      -7.131471       3.835476

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.72     0.4750
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.700617      17.883173      27.018821   166.19       0.510852       0.345946       0.982997


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.923353       5.197963     -14.1859     6.339199   166.19      -7.338630       3.629290

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=0 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.75     0.4514
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694480      18.536365      27.665569   174.49       0.492502       0.337534       0.983403


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.405734       5.259807     -9.97530     10.78677   174.49      -3.006453       7.945337

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.08     0.9386
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694629      18.383800      27.513161   172.57       0.496598       0.339430       0.983312


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.198840       5.245299     -10.1544     10.55204   172.57      -3.212882       7.739151

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.04     0.9698
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694782      18.243342      27.372863    170.8       0.500430       0.341194       0.983226


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.008054       5.231908     -10.3356     10.31947    170.8      -3.420040       7.532965

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.00     0.9988
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694937      18.114992      27.244676    169.2       0.503985       0.342822       0.983148


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.214947       5.219643     -10.5190     10.08906    169.2      -3.627198       7.326779

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.04     0.9672
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695096      17.998748      27.128599   167.76       0.507249       0.344311       0.983076


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.421841       5.208512     -10.7045     9.860835   167.76      -3.834357       7.120594

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.08     0.9355
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695258      17.894611      27.024632   166.47       0.510211       0.345655       0.983011


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.628734       5.198522     -10.8923     9.634797   166.47      -4.041515       6.914408

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.12     0.9039
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695423      17.802582      26.932776   165.33       0.512858       0.346853       0.982953


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.835628       5.189680     -11.0822     9.410961   165.33      -4.248673       6.708222

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.16     0.8723
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695591      17.722659      26.853029   164.35       0.515181       0.347900       0.982902


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.042521       5.181991     -11.2744     9.189338   164.35      -4.455831       6.502036

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.20     0.8408
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695762      17.654843      26.785393   163.51       0.517170       0.348795       0.982859


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.249415       5.175461     -11.4688     8.969937   163.51      -4.662990       6.295851

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.24     0.8095
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695936      17.599134      26.729868   162.83       0.518817       0.349534       0.982824


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.456308       5.170094     -11.6654     8.752765   162.83      -4.870148       6.089665

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.28     0.7785
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.696114      17.555533      26.686452    162.3       0.520116       0.350115       0.982795


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.663202       5.165893     -11.8642     8.537829    162.3      -5.077306       5.883479

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.32     0.7479
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.696294      17.524038      26.655147   161.91       0.521062       0.350538       0.982775


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.870096       5.162862     -12.0653     8.325134   161.91      -5.284464       5.677294

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.36     0.7177
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.696478      17.504650      26.635952   161.67       0.521650       0.350801       0.982762


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.076989       5.161003     -12.2687     8.114682   161.67      -5.491623       5.471108

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.40     0.6879
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.696665      17.497369      26.628867   161.58       0.521878       0.350902       0.982757


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.283883       5.160317     -12.4742     7.906477   161.58      -5.698781       5.264922

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.44     0.6587
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.696855      17.502196      26.633893   161.63       0.521746       0.350843       0.982760


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.490776       5.160804     -12.6821     7.700520   161.63      -5.905939       5.058736

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=0.6 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.48     0.6300
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697048      17.519129      26.651029   161.83       0.521253       0.350623       0.982771


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.697670       5.162463     -12.8921     7.496809   161.83      -6.113098       4.852551

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.52     0.6020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697244      17.548169      26.680275   162.18       0.520402       0.350243       0.982789


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.904563       5.165295     -13.1045     7.295342   162.18      -6.320256       4.646365

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.56     0.5747
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697443      17.589316      26.721632   162.67       0.519197       0.349704       0.982815


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.111457       5.169297     -13.3190     7.096117   162.67      -6.527414       4.440179

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.60     0.5481
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697645      17.642571      26.775098   163.32       0.517642       0.349006       0.982849


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.318351       5.174466     -13.5358     6.899129   163.32      -6.734572       4.233993

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.64     0.5222
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.697851      17.707932      26.840675   164.11       0.515743       0.348153       0.982890


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.525244       5.180799     -13.7549     6.704371   164.11      -6.941731       4.027808

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.68     0.4972
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.698059      17.785400      26.918362   165.05       0.513509       0.347147       0.982939


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.732138       5.188291     -13.9761     6.511836   165.05      -7.148889       3.821622

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=0.6 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.72     0.4729
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.691777      18.449048      27.575413   173.46       0.494680       0.338543       0.983355


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.596949       5.251230     -9.76758     10.96148   173.46      -2.815983       8.137668

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.11     0.9096
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.691935      18.296592      27.423124   171.54       0.498810       0.340449       0.983262


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.390056       5.236709     -9.94663     10.72674   171.54      -3.023141       7.931483

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.07     0.9407
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692096      18.156244      27.282945   169.79       0.502676       0.342223       0.983177


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.183162       5.223308     -10.1278     10.49415   169.79      -3.230299       7.725297

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.04     0.9721
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692260      18.028003      27.154876   168.19       0.506261       0.343861       0.983098


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.023731       5.211034     -10.3112     10.26373   168.19      -3.437457       7.519111

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.00     0.9964
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692428      17.911868      27.038917   166.75       0.509553       0.345357       0.983025


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.230625       5.199896     -10.4967     10.03549   166.75      -3.644616       7.312925

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.04     0.9647
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692598      17.807841      26.935069   165.47       0.512540       0.346709       0.982960


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.437519       5.189901     -10.6845     9.809444   165.47      -3.851774       7.106740

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.08     0.9329
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692772      17.715921      26.843331   164.34       0.515209       0.347913       0.982902


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.644412       5.181055     -10.8744     9.585605   164.34      -4.058932       6.900554

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.12     0.9012
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692948      17.636108      26.763703   163.36       0.517552       0.348966       0.982851


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.851306       5.173365     -11.0666     9.363982   163.36      -4.266090       6.694368

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.16     0.8695
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.693128      17.568401      26.696186   162.53       0.519557       0.349865       0.982808


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.058199       5.166835     -11.2610     9.144584   162.53      -4.473249       6.488182

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.20     0.8380
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.693311      17.512802      26.640779   161.84       0.521217       0.350607       0.982772


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.265093       5.161471     -11.4576     8.927418   161.84      -4.680407       6.281997

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.25     0.8067
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.693497      17.469310      26.597482   161.31       0.522526       0.351191       0.982743


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.471986       5.157275     -11.6565     8.712492   161.31      -4.887565       6.075811

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.29     0.7757
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.693686      17.437924      26.566295   160.93       0.523478       0.351616       0.982723


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.678880       5.154250     -11.8576     8.499810   160.93      -5.094724       5.869625

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.33     0.7451
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.693878      17.418646      26.547218   160.69       0.524069       0.351879       0.982710


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.885774       5.152399     -12.0609     8.289375   160.69      -5.301882       5.663439

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.37     0.7148
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694074      17.411475      26.540252    160.6       0.524297       0.351980       0.982705


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.092667       5.151723     -12.2665     8.081191    160.6      -5.509040       5.457254

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.41     0.6851
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694272      17.416411      26.545396   160.65       0.524160       0.351919       0.982708


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.299561       5.152222     -12.4744     7.875257   160.65      -5.716198       5.251068

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.2 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.45     0.6560
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694474      17.433453      26.562651   160.85       0.523660       0.351696       0.982719


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.506454       5.153897     -12.6845     7.671573   160.85      -5.923357       5.044882

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.49     0.6274
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694679      17.462603      26.592015    161.2       0.522798       0.351313       0.982738


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.713348       5.156745     -12.8968     7.470137    161.2      -6.130515       4.838697

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.53     0.5995
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.694886      17.503860      26.633490    161.7       0.521578       0.350768       0.982764


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.920241       5.160765     -13.1114     7.270945    161.7      -6.337673       4.632511

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5723
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695097      17.557223      26.687075   162.34       0.520005       0.350066       0.982798


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.127135       5.165953     -13.3283     7.073994   162.34      -6.544832       4.426325

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.61     0.5458
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695311      17.622694      26.752771   163.13       0.518086       0.349206       0.982839


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.334028       5.172308     -13.5473     6.879276   163.13      -6.751990       4.220139

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.64     0.5201
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.695528      17.700272      26.830577   164.08       0.515829       0.348192       0.982888


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.540922       5.179824     -13.7686     6.686785   164.08      -6.959148       4.013954

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.2 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.68     0.4952
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689102      18.374374      27.497931   172.59       0.496537       0.339402       0.983313


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.788165       5.243847     -9.56216     11.13849   172.59      -2.626242       8.330000

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.15     0.8807
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689268      18.222028      27.345760   170.68       0.500698       0.341317       0.983221


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.581271       5.229317     -9.74119     10.90374   170.68      -2.833400       8.123814

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.11     0.9116
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689438      18.081790      27.205699   168.93       0.504591       0.343099       0.983134


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.374378       5.215908     -9.92238     10.67113   168.93      -3.040558       7.917628

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.07     0.9429
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689611      17.953658      27.077749   167.34       0.508202       0.344744       0.983055


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.167484       5.203628     -10.1057     10.44070   167.34      -3.247717       7.711443

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.03     0.9744
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689787      17.837633      26.961909    165.9       0.511518       0.346247       0.982982


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.039409       5.192486     -10.2913     10.21246    165.9      -3.454875       7.505257

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.01     0.9940
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689966      17.733715      26.858179   164.62       0.514526       0.347606       0.982917


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.246303       5.182488     -10.4790     9.986410   164.62      -3.662033       7.299071

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.05     0.9622
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690148      17.641904      26.766559    163.5       0.517215       0.348815       0.982858


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.453196       5.173641     -10.6690     9.762571    163.5      -3.869191       7.092885

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.09     0.9303
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690333      17.562200      26.687050   162.52       0.519573       0.349872       0.982807


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.660090       5.165951     -10.8611     9.540950   162.52      -4.076350       6.886700

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.13     0.8985
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690521      17.494603      26.619651   161.69       0.521592       0.350775       0.982764


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.866984       5.159424     -11.0555     9.321558   161.69      -4.283508       6.680514

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.17     0.8668
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690713      17.439114      26.564362   161.01       0.523263       0.351520       0.982728


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.073877       5.154063     -11.2522     9.104401   161.01      -4.490666       6.474328

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.21     0.8352
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690908      17.395731      26.521184   160.48       0.524580       0.352106       0.982699


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.280771       5.149872     -11.4510     8.889486   160.48      -4.697824       6.268143

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.25     0.8039
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.691105      17.364455      26.490116    160.1       0.525537       0.352531       0.982679


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.487664       5.146855     -11.6521     8.676819    160.1      -4.904983       6.061957

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.29     0.7729
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.691306      17.345286      26.471158   159.86       0.526130       0.352794       0.982666


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.694558       5.145013     -11.8555     8.466402   159.86      -5.112141       5.855771

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.33     0.7423
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.691510      17.338224      26.464310   159.77       0.526356       0.352895       0.982661


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.901451       5.144347     -12.0611     8.258238   159.77      -5.319299       5.649585

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.37     0.7122
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.691717      17.343269      26.469572   159.83       0.526216       0.352833       0.982664


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.108345       5.144859     -12.2690     8.052327   159.83      -5.526458       5.443400

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=1.8 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.41     0.6825
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.691927      17.360422      26.486945   160.03       0.525709       0.352607       0.982675


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.315239       5.146547     -12.4791     7.848670   160.03      -5.733616       5.237214

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.45     0.6534
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692141      17.389681      26.516428   160.38       0.524837       0.352220       0.982694


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.522132       5.149410     -12.6915     7.647263   160.38      -5.940774       5.031028

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.49     0.6250
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692357      17.431047      26.558022   160.88       0.523605       0.351672       0.982720


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.729026       5.153448     -12.9062     7.448104   160.88      -6.147932       4.824842

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.53     0.5972
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692577      17.484520      26.611725   161.52       0.522016       0.350964       0.982754


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.935919       5.158655     -13.1230     7.251187   161.52      -6.355091       4.618657

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5701
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.692799      17.550100      26.677539   162.31       0.520079       0.350099       0.982796


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.142813       5.165030     -13.3421     7.056507   162.31      -6.562249       4.412471

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.61     0.5437
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.693025      17.627787      26.755463   163.25       0.517800       0.349078       0.982846


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.349706       5.172568     -13.5635     6.864057   163.25      -6.769407       4.206285

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=1.8 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.65     0.5182
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686453      18.312345      27.433121   171.89       0.498067       0.340107       0.983279


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.979381       5.237664     -9.35904     11.31780   171.89      -2.436501       8.522332

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=-9 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.19     0.8519
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686629      18.160108      27.281068   169.98       0.502253       0.342029       0.983186


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.772487       5.223128     -9.53806     11.08304   169.98      -2.643659       8.316146

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-8.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.15     0.8826
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686807      18.019979      27.141126   168.23       0.506169       0.343818       0.983100


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.565593       5.209715     -9.71924     10.85043   168.23      -2.850817       8.109960

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-7.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.11     0.9137
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686988      17.891957      27.013294   166.64       0.509801       0.345470       0.983020


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.358700       5.197432     -9.90260     10.62000   166.64      -3.057976       7.903774

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-7.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.07     0.9451
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687173      17.776041      26.897573   165.21       0.513136       0.346979       0.982947


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.151806       5.186287     -10.0881     10.39175   165.21      -3.265134       7.697589

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-6.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.03     0.9767
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687361      17.672233      26.793961   163.94       0.516162       0.348342       0.982881


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.055087       5.176288     -10.2759     10.16570   163.94      -3.472292       7.491403

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=-6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.01     0.9915
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687551      17.580531      26.702460   162.81       0.518865       0.349555       0.982822


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.261981       5.167442     -10.4658     9.941867   162.81      -3.679451       7.285217

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-5.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.05     0.9596
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687745      17.500937      26.623069   161.84       0.521237       0.350616       0.982771


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.468874       5.159755     -10.6580     9.720252   161.84      -3.886609       7.079031

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-4.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.09     0.9277
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687942      17.433450      26.555789   161.01       0.523266       0.351521       0.982728


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.675768       5.153231     -10.8524     9.500868   161.01      -4.093767       6.872846

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-4.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.13     0.8958
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.688142      17.378069      26.500619   160.34       0.524946       0.352269       0.982691


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.882661       5.147875     -11.0490     9.283722   160.34      -4.300925       6.666660

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-3.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.17     0.8641
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.688345      17.334796      26.457559   159.81       0.526269       0.352856       0.982663


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.089555       5.143691     -11.2479     9.068821   159.81      -4.508084       6.460474

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=-3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.21     0.8325
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.688552      17.303629      26.426609   159.43       0.527229       0.353282       0.982643


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.296449       5.140682     -11.4491     8.856170   159.43      -4.715242       6.254288

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.25     0.8012
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.688761      17.284570      26.407769   159.19       0.527823       0.353545       0.982630


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.503342       5.138849     -11.6525     8.645771   159.19      -4.922400       6.048103

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.29     0.7703
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.688974      17.277618      26.401040    159.1       0.528049       0.353645       0.982625


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.710236       5.138194     -11.8581     8.437628    159.1      -5.129558       5.841917

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.33     0.7397
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689189      17.282772      26.406421   159.16       0.527904       0.353581       0.982628


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.917129       5.138718     -12.0660     8.231740   159.16      -5.336717       5.635731

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------ avisitn=12 SHIFT1=2.4 SHIFT0=-0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.37     0.7096
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689408      17.300034      26.423912   159.36       0.527391       0.353353       0.982639


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.124023       5.140419     -12.2762     8.028109   159.36      -5.543875       5.429546

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=0 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.41     0.6800
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689630      17.329402      26.453514   159.71       0.526510       0.352963       0.982658


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.330916       5.143298     -12.4886     7.826730   159.71      -5.751033       5.223360

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=0.6 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.45     0.6510
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.689855      17.370878      26.495226   160.21       0.525267       0.352411       0.982685


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.537810       5.147351     -12.7032     7.627601   160.21      -5.958192       5.017174

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=1.2 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.49     0.6227
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690083      17.424461      26.549048   160.85       0.523665       0.351699       0.982719


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.744704       5.152577     -12.9201     7.430718   160.85      -6.165350       4.810988

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=1.8 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.53     0.5950
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690314      17.490150      26.614980   161.64       0.521713       0.350828       0.982761


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.951597       5.158971     -13.1393     7.236073   161.64      -6.372508       4.604803

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=2.4 -------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5680
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.690549      17.567947      26.693023   162.58       0.519416       0.349802       0.982811


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -3.158491       5.166529     -13.3606     7.043660   162.58      -6.579666       4.398617

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=2.4 SHIFT0=3 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.61     0.5418
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-9 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.683833      18.262959      27.380984   171.34       0.499263       0.340658       0.983252


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         1.170596       5.232684     -9.15823     11.49942   171.34      -2.246760       8.714663

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-9 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.22     0.8233
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-8.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.684016      18.110832      27.229050   169.43       0.503468       0.342586       0.983159


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.963703       5.218146     -9.33725     11.26466   169.43      -2.453918       8.508477

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-8.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.18     0.8537
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-7.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.684203      17.970813      27.089226   167.69       0.507401       0.344380       0.983072


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.756809       5.204731     -9.51843     11.03205   167.69      -2.661077       8.302292

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-7.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.15     0.8846
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-7.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.684393      17.842900      26.961513   166.11       0.511050       0.346035       0.982992


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.549916       5.192448     -9.70179     10.80162   166.11      -2.868235       8.096106

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-7.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.11     0.9158
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-6.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.684586      17.727094      26.845909   164.68       0.514400       0.347549       0.982919


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.343022       5.181304     -9.88733     10.57337   164.68      -3.075393       7.889920

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-6.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.07     0.9473
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-6 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.684783      17.623395      26.742416    163.4       0.517438       0.348915       0.982853


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE         0.136128       5.171307     -10.0751     10.34733    163.4      -3.282551       7.683735

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-6 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0               0.03     0.9790
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-5.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.684982      17.531803      26.651034   162.28       0.520154       0.350132       0.982795


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.070765       5.162464     -10.2650     10.12350   162.28      -3.489710       7.477549

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-5.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.01     0.9891
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-4.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.685184      17.452318      26.571761   161.31       0.522535       0.351195       0.982743


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.277659       5.154780     -10.4572     9.901896   161.31      -3.696868       7.271363

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-4.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.05     0.9571
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-4.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.685390      17.384940      26.504599   160.49       0.524572       0.352103       0.982699


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.484552       5.148262     -10.6516     9.682523   160.49      -3.904026       7.065177

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-4.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.09     0.9251
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-3.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.685599      17.329669      26.449548   159.81       0.526258       0.352851       0.982663


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.691446       5.142912     -10.8483     9.465390   159.81      -4.111185       6.858992

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-3.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.13     0.8932
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.685811      17.286505      26.406606   159.29       0.527585       0.353440       0.982635


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -0.898339       5.138736     -11.0472     9.250504   159.29      -4.318343       6.652806

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.17     0.8614
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686025      17.255448      26.375775   158.91       0.528548       0.353866       0.982614


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.105233       5.135735     -11.2483     9.037870   158.91      -4.525501       6.446620

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.22     0.8299
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686243      17.236498      26.357054   158.67       0.529142       0.354128       0.982602


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.312127       5.133912     -11.4517     8.827490   158.67      -4.732659       6.240434

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.26     0.7986
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686465      17.229655      26.350443   158.59       0.529366       0.354227       0.982597


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.519020       5.133268     -11.6574     8.619368   158.59      -4.939818       6.034249

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.30     0.7677
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686689      17.234919      26.355942   158.64       0.529218       0.354162       0.982600


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.725914       5.133804     -11.8653     8.413504   158.64      -5.146976       5.828063

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=-0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.34     0.7372
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.686916      17.252290      26.373552   158.85       0.528699       0.353932       0.982611


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -1.932807       5.135519     -12.0755     8.209897   158.85      -5.354134       5.621877

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=0 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.38     0.7072
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687147      17.281768      26.403272    159.2       0.527811       0.353539       0.982630


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.139701       5.138411     -12.2879     8.008546    159.2      -5.561292       5.415691

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=0.6 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.42     0.6777
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687380      17.323353      26.445102   159.69       0.526558       0.352984       0.982657


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.346594       5.142480     -12.5026     7.809446   159.69      -5.768451       5.209506

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=1.2 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.46     0.6488
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687617      17.377045      26.499043   160.34       0.524945       0.352268       0.982691


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.553488       5.147722     -12.7196     7.612594   160.34      -5.975609       5.003320

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=1.8 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.50     0.6205
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.687857      17.442844      26.565094   161.13       0.522979       0.351393       0.982734


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.760381       5.154134     -12.9387     7.417982   161.13      -6.182767       4.797134

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

-------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=2.4 --------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.54     0.5930
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                                         Model Information

                                              Data Set                  WORK.LSDIFFS2
                                              Number of Imputations     20           


                                               Variance Information (20 Imputations)
 
                                                                                  Relative       Fraction
                        -----------------Variance-----------------                Increase        Missing       Relative
           Parameter         Between         Within          Total       DF    in Variance    Information     Efficiency

           ESTIMATE         8.688100      17.520750      26.643255   162.07       0.520669       0.350362       0.982783


                                               Parameter Estimates (20 Imputations)
 
             Parameter        Estimate      Std Error    95% Confidence Limits        DF        Minimum        Maximum

             ESTIMATE        -2.967275       5.161710     -13.1602     7.225603   162.07      -6.389926       4.590949

 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
                       ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Jazz PharmaceuticalsPage ^{pageof}
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Protocol 150-201
                                ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Table 9.2.1.2.2  
^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}Primary Efficacy Endpoint, Change in the  CAPS-5 Total Score from Baseline to Wee
                          ^S={fontstyle=ROMAN fontsize=10pt font_weight=bold}(Modified Full Analysis Set)

--------------------------------------------------- avisitn=12 SHIFT1=3 SHIFT0=3 ---------------------------------------------------

                                                      The MIANALYZE Procedure

                                               Parameter Estimates (20 Imputations)
 
                                                                         t for H0:
                                      Parameter          Theta0   Parameter=Theta0   Pr > |t|

                                      ESTIMATE                0              -0.57     0.5662
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
^S={}CAPS-5: Clinician Administered PTSD Scale; CAPS-5 Total Score: CAPS-5 total symptom severity score; MAR: Missing at random; MMR
^S={}Note: The 2-dimensional tipping point analysis is only performed for the dose(s) in the primary efficacy estimand that achieves
^S={}Note: A delta (a multiple of the observed treatment effect) will be added to Week 12 for both JZP150 and placebo arms prior to 
                                                              ^S={}

^S={}PROGRAM NAME: C:\SASData\JZP-150\150-201\stat\csr_dryrun1\pgm\tlf\t_caps5_totscr_mfasfl_sens_tipping.sas     DATE: 31JAN2023:08
